Veltuzumab: Phase II discontinued

Immunomedics said in its 1Q13 earnings ending Sept. 30 that Takeda's Nycomed unit discontinued the Phase II VELVET trial of veltuzumab and will "redesign the study protocol and start a new trial as soon as possible." Immunomedics said that in November 2011 enrollment was discontinued in the double-blind, placebo-controlled, international VELVET trial, which had enrolled 11 patients and was evaluating 80, 160 and 320 mg subcutaneous veltuzumab once weekly for 4 weeks as an add-on to methotrexate. Immunomedics said the new trial will use veltuzumab supplied from Nycomed's commercial-scale manufacturer. The companies could not be reached for details. ...